Ann: FDA Notifies Clinical Data Sufficient for Refiling aGVHD BLA, page-553

My following two posts are long because I’m trying to establish that Ryoncil is about a lot more than acute GvHD, the lead candidate of a precious acute platform. They're from the perspective of medical insurers who have a direct window onto the real world. I think this must be the most cynical jaded group who are surely aware that for a long time they’ve been paying out for marketing over substance.

IMO, it’s about more than acute GvHD. I’m looking mainly for evidence of Ryoncil as a prophylactic for chronic GvHD but beyond that.

We live in a world where the picture painted by statistics often doesn’t match reality. Please be aware the second post contains distressing details about chronic GVHD.

I have no doubt of a bad situation n IBD, especially pediatrics. I’m not advocating pestering doctors but if you get the opportunity to speak to a colorectal surgeon, ask them about the incidence of colectomies/resections since the advent of the “revolutionary” biologics.